BMS-936558 is an investigational anticancer drug that boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells. BMS-936558 binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells.
In this study, researchers are comparing the effectiveness of BMS-936558 to that of docetaxel, a standard chemotherapy drug, in patients with advanced squamous cell lung cancer that persists despite prior therapy. Patients will be randomly assigned to receive BMS-936558 or docetaxel, but not both. Both drugs are given intravenously (by vein).